Report of Foreign Issuer (6-k)
June 11 2018 - 3:07PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
REPORT
OF FOREIGN PRIVATE ISSUER
Pursuant
to Rule 13a-16 or 15d-16 of the
Securities
Exchange Act of 1934
For
the month of June 2018
Commission
File Number: 001-36581
Vascular
Biogenics Ltd.
(Translation
of registrant’s name into English)
8
HaSatat St.
Modi’in
Israel
7178106
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form
20-F [X] Form 40-F [ ]
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): [ ]
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): [ ]
Indicate
by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes
[ ] No [X]
If
“Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-
RESIGNATION
OF DIRECTOR
On
June 7, 2018, Philip Serlin notified Vascular Biogenics Ltd. (the “Company”) of his resignation from the
Company’s Board of Directors (the “Board”). Mr. Serlin’s resignation did not result from any
disagreement with the Company on any matter relating to the Company’s operations, policies or practices. The Company
thanks Mr. Serlin for his service on the Board and contribution to the Company. The Company hereby incorporates by
reference the information contained herein into the Company’s registration statement on Form F-3 (File No. 333-222138)
and registration statement on Form F-3 (File No. 333- 207250).
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
VASCULAR
BIOGENICS LTD.
|
|
|
|
Date:
June 11, 2018
|
By:
|
/s/
Dror Harats
|
|
Name:
|
Dror
Harats
|
|
Title:
|
Chief
Executive Officer
|
Vascular Biogenics (NASDAQ:VBLT)
Historical Stock Chart
From Apr 2024 to May 2024
Vascular Biogenics (NASDAQ:VBLT)
Historical Stock Chart
From May 2023 to May 2024